We have a prototype of a Polish vaccine against the SARS-CoV-2 coronavirus, we move to the phase of the molecular characteristics and clinical trials, Professor Andrzej Mackiewicz, an oncologist and immunologist announced.
He is the leader of the team of scientists from the Medical Biology Centre of Poznań Medical University, which is working on a vaccine against the virus. The Polish vaccine will differ from those prepared by Chinese or American specialists.
“They focus on preventing contraction by antibodies targeted on the SARS-CoV-2 coronavirus. But recent reports show that some COVID-19 patients do not produce antibodies and the fight against the disease is conducted by immune system cells. Moreover, antibodies from those who recovered or those created artificially show very limited effectiveness,” Professor Mackiewicz said.
According to him, the Polish vaccine, apart from supporting the creation of antibodies, will also activate so-called cell defence mechanisms targeted selectively at the virus.
“Our vaccine, called CovidVax starts similar immunologic mechanisms as cancer vaccines we have produced for 30 years,” he stressed.
For the current stage of this research, the team created two kinds of the vaccine: for humans and mice.
“In two weeks’ time, we will apply the vaccine to animals to verify the immune mechanisms we expect to work. This will be the base to monitor the vaccine in humans’ clinical trials,” Prof. Mackiewicz said.
“Creating a Polish vaccine is very important because other countries will apply their product to their own citizens first... and buying them would be like buying a pig in a poke, because we would not know about the effectiveness of those vaccines,” he added.